October 9, 2018

San Francisco, California

Patient Centric Drug Development in the Digital Era

 

Translational Science Forum

 

Welcome

 

3rd Annual MedImmune California Translational Science Forum:

Patient-​Centric Drug Development in the Digital Era

 

MedImmune, the global biologics research and development arm of AstraZeneca, is hosting a one-​​day Translational Science Forum in the Bay Area, gathering academic institutions, industry leaders, and other experts in the drug development ecosystem to assess a critical question: How are digital technologies transforming patients’ and drug developers’ understanding of diseases and treatment options?

As the “one-​size-​fit-​all” approach to drug development becomes a thing of the past, the Forum will address:

     

  • How can scientists successfully embrace the new patient centric drug development paradigm and put patients first?

  • How can scientists get novel insights into diseases and better predict disease progressions and outcomes by leveraging data science, bioinformatics, and digital tools (such as machine learning and AI)?  

  •  

This forum will highlight digital transformation in various stages of the drug development process and showcase advances in technology that brings patient centricity to reality.

The Translational Science Forum will provide attendees an opportunity to:

     

  • Hear PRESENTATIONS from leading and forward-​thinking experts;

  • Interact and engage experts during extended Q&As and RECEPTION sessions;

  • NETWORK and COLLABORATE with digital health experts from the Bay Area biotech hub and surrounding areas.

  •  


Please complete your registration today to confirm your attendance!

 

 

 

 

 

 

 

 

 

 

Disclaimers

 

The Company has undertaken reasonable efforts to include accurate and up-​to-​date information on its Web site. However, THIS WEB SITE IS PROVIDED "AS IS" AND THE COMPANY MAKES NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-​INFRINGEMENT. THE COMPANY DOES NOT WARRANT THAT THE FUNCTIONS CONTAINED IN THE WEB SITE WILL BE UNINTERRUPTED OR ERROR FREE OR THAT THE WEB SITE OR THE SERVER THAT MAKES IT AVAILABLE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OF IMPLIED WARRANTIES, SO THE ABOVE EXCLUSION MAY NOT APPLY TO YOU. All users agree that all access and use of this Web site and its content is at their own risk.

 

Neither the Company nor any other party involved in creating, producing or delivering this Web site shall be liable in any manner for any direct, incidental, consequential, indirect or punitive damages arising out of your access, use or inability to use this Web site, or any errors or omissions in the content.

 

This Web site may provide links or references to other Internet sites maintained by third parties over whom the Company has no control. Such links are provided merely as a convenience to users of this Web site. The Company takes no responsibility for the content of such sites and makes no representations as to the accuracy or completeness of any information contained in such sites, and shall have no liability for any damages or injuries of any kind arising from such content or information.

 

For more information, please visit https://www.astrazeneca-​us.com/legal-​notice.html

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Mission Bay Conference Center at UCSF

 

Tuesday, October 9
.

7:00am -​ 6:30pm

© MedImmune 2018